Check Claims Before You Publish

Key high‑quality contributions (selected highly‑cited works)

• NEJM randomized trial report (REDUCE/dutasteride) — major RCT with >1,000 citations and continuing influence on prostate cancer chemoprevention research NEJM Dutasteride Trial
• JAMA review on low‑dose CT for lung cancer screening — balanced evidence synthesis used by guideline panels to evaluate population screening tradeoffs JAMA CT Lung‑Screening Review
• American Cancer Society screening guideline updates (colorectal and general screening reviews) — synthesis articles with high translational impact and large reference lists used by clinicians and policymakers ACS Colorectal Guideline 2018

Strengths — evidence‑based evaluation

• High translational impact: multiple guideline/review papers with >1,000 citations each, indicating broad influence on screening and clinical practice (ACS Guideline).
• Work spans RCT commentary, systematic evidence synthesis, and population/epidemiologic studies — demonstrates methodological breadth (randomized trials, systematic reviews, population data analyses) NEJM Dutasteride TrialJAMA Lung Screening Review.

Limitations, blindspots, and biases to watch

• Authorship on large guideline papers often includes many co‑authors; disentangling the extent of individual intellectual leadership versus group consensus requires caution — credit is shared across teams (author position varies across works).
• Guideline and review papers are high‑impact but can reflect available evidence at time of writing; their conclusions evolve as new trials or meta‑analyses appear (temporal knowledge half‑life risk).
• Potential conflicts of interest and funding influence are common risks in guideline/clinical trial literature; transparency statements should be inspected per paper (we flagged trial and guideline sources above for scrutiny) NEJM Dutasteride Trial (COI note).

Citation‑metric note (reconciling sources)

Provided OpenAlex data in the prompt reports an author entity with works_count ~220, cited_by_count ~17,779 and h_index ~57, and multiple top works with very large citation counts; those per‑paper DOIs above confirm several high‑impact publications (NEJM, JAMA, CA A Cancer J Clinicians) that explain high citation totals. For specific per‑year citation counts we plotted the OpenAlex yearly cited_by_count vector supplied in your input (above graph).

Case example: race & prostate cancer commentary (JAMA Oncology commentary)

Bottom line — scientific strength

Otis W. Brawley is a scientifically influential clinician‑scientist and policy author with multiple high‑impact, highly‑cited works in oncology, cancer screening, and population health; his portfolio combines randomized‑trial involvement, systematic evidence synthesis, and policy/guideline authorship — strengths that produce high translational impact but also require careful reading to separate individual contribution from multi‑author consensus and to inspect COI and evolving evidence. The long citation record and presence in major journals (NEJM, JAMA, CA) support a high scientific influence in clinical oncology and cancer epidemiology NEJM Dutasteride TrialJAMA CT Screening Review

What would change this evaluation?

1. Evidence that major guideline positions were invalidated by subsequent higher‑quality randomized trials would reduce confidence in translational judgments.
2. Clear documentation that individual contributions to highly cited multi‑author guideline papers were minimal would lower assessment of personal scientific leadership.